StreetInsider.com News Articles

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: RA Capital Healthcare Fund LP

Fri, 12 Jun 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260612/26642640.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: RA Capital Healthcare Fund LP

Fri, 12 Jun 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260612/26642640.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Detheux Michel

Fri, 12 Jun 2026 20:43:00 -0400

si-local-file:///var/storage/secattach/20260612/26642639.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Detheux Michel

Fri, 12 Jun 2026 20:43:00 -0400

si-local-file:///var/storage/secattach/20260612/26642639.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Joustra Wouter

Fri, 12 Jun 2026 20:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26642637.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Joustra Wouter

Fri, 12 Jun 2026 20:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26642637.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Namouni Fouad

Fri, 12 Jun 2026 20:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26642638.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Namouni Fouad

Fri, 12 Jun 2026 20:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26642638.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Cumbo Alexander

Fri, 12 Jun 2026 20:41:00 -0400

si-local-file:///var/storage/secattach/20260612/26642634.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Cumbo Alexander

Fri, 12 Jun 2026 20:41:00 -0400

si-local-file:///var/storage/secattach/20260612/26642634.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Kalir Erez

Fri, 12 Jun 2026 20:41:00 -0400

si-local-file:///var/storage/secattach/20260612/26642636.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Kalir Erez

Fri, 12 Jun 2026 20:41:00 -0400

si-local-file:///var/storage/secattach/20260612/26642636.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Levin Andrew David

Fri, 12 Jun 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26642631.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Levin Andrew David

Fri, 12 Jun 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26642631.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Beckman Daniella

Fri, 12 Jun 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26642633.html

Form 4 Vor Biopharma Inc. For: Jun 11 Filed by: Beckman Daniella

Fri, 12 Jun 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26642633.html

Form 8-K Vor Biopharma Inc. For: Jun 11

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640880.html

Form 8-K Vor Biopharma Inc. For: Jun 11

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640880.html

Form 8-K Vor Biopharma Inc. For: Jun 08

Mon, 08 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260608/26617144.html

Form 8-K Vor Biopharma Inc. For: Jun 08

Mon, 08 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260608/26617144.html

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Mon, 08 Jun 2026 08:31:00 -0400

First regulatory approval for Sjögren’s disease (SjD)

First and only approved therapy for SjD in China

Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI

SjD marks the fifth indication approval for telitacicept

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China’s National Medicinal Products Administration (NMPA) has approved telitacicept

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Mon, 08 Jun 2026 08:31:00 -0400

First regulatory approval for Sjögren’s disease (SjD)

First and only approved therapy for SjD in China

Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI

SjD marks the fifth indication approval for telitacicept

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Mon, 08 Jun 2026 08:31:00 -0400

First regulatory approval for Sjögren’s disease (SjD)

First and only approved therapy for SjD in China

Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI

SjD marks the fifth indication approval for telitacicept

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Mon, 08 Jun 2026 08:31:00 -0400

First regulatory approval for Sjögren’s disease (SjD)

First and only approved therapy for SjD in China

Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI

SjD marks the fifth indication approval for telitacicept

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Mon, 08 Jun 2026 08:31:00 -0400

First regulatory approval for Sjögren’s disease (SjD)

First and only approved therapy for SjD in China

Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI

SjD marks the fifth indication approval for telitacicept